Valuation: Autolus Therapeutics plc

Market Cap 34Cr 31Cr 28Cr 25Cr 48Cr 3.2TCr 50Cr 336.6Cr 134.22Cr 1.71TCr 127.88Cr 125.13Cr 5.39TCr P/E 2026 *
-1.58x
P/E 2027 * -1.85x
Enterprise Value 19Cr 17Cr 15Cr 14Cr 27Cr 1.77TCr 27Cr 186.07Cr 74Cr 944.63Cr 71Cr 69Cr 2.98TCr EV / Sales 2026 *
1.26x
EV / Sales 2027 * 1.38x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+1.59%
1 week-15.79%
Current month-15.79%
1 month-29.28%
3 months-39.34%
6 months-20.50%
Current year-35.68%
1 week 1.22
Extreme 1.225
1.56
1 month 1.22
Extreme 1.225
1.82
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.45
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Executive/Senior Manager

-6,713 0.0025%
29/06/26 Free

Director

79,167 0.0477%
18/03/26 Other

Chief Executive Officer

69,17,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
+1.59%-15.79%-3.76%-65.22% 34Cr
-0.79%-4.48%+46.48%+125.69% 1,20600Cr
+1.43%+1.11%+48.05%+83.05% 66TCr
+1.07%-1.21%+32.92%+104.92% 51TCr
-0.36%-3.25%+45.42%+65.10% 38TCr
-0.14%-1.87%+70.06%+41.09% 36TCr
-0.78%-0.52%+30.47%+58.09% 31TCr
-0.80%-0.21%+7.98%+36.17% 29TCr
+0.03%-1.20%+43.79%+69.83% 25TCr
-0.41%-2.22%+40.43%+107.03% 21TCr
Average +0.08%-2.96%+36.19%+62.57% 41.8TCr
Weighted average by Cap. -0.04%-1.96%+42.71%+88.10%

Financials

2026 *2027 *
Net sales 15Cr 13Cr 12Cr 11Cr 21Cr 1.41TCr 22Cr 147.98Cr 59Cr 751.25Cr 56Cr 55Cr 2.37TCr 19Cr 17Cr 16Cr 14Cr 27Cr 1.81TCr 28Cr 190.11Cr 76Cr 965.13Cr 72Cr 71Cr 3.05TCr
Net income -22Cr -20Cr -18Cr -16Cr -31Cr -2.07TCr -32Cr -217.23Cr -87Cr -1.1TCr -83Cr -81Cr -3.48TCr -19Cr -17Cr -15Cr -14Cr -26Cr -1.76TCr -27Cr -185.21Cr -74Cr -940.26Cr -70Cr -69Cr -2.97TCr
Net Debt -15Cr -14Cr -12Cr -11Cr -21Cr -1.43TCr -22Cr -150.53Cr -60Cr -764.18Cr -57Cr -56Cr -2.41TCr -7.51Cr -6.74Cr -6.16Cr -5.62Cr -11Cr -706.07Cr -11Cr -74Cr -30Cr -376.74Cr -28Cr -28Cr -1.19TCr
Projected Income Statement - Annual - Autolus Therapeutics plc
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
06/26/06 $1.280 +1.59% 12,04,146
05/26/05 $1.260 -8.70% 31,32,627
04/26/04 $1.380 -2.47% 27,69,098
03/26/03 $1.415 -0.35% 28,83,272
02/26/02 $1.420 -6.58% 47,04,296
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.280USD
Average target price
8.750USD
Spread / Average Target
+583.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Autolus Therapeutics plc
  1. Stock Market
  2. Stocks
  3. AUTL Stock